Rockefeller Capital Management
NRIX icon

Rockefeller Capital Management’s Nurix Therapeutics NRIX Stock Holding History

Rockefeller Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$129K Hold
5,318
– – ﹤0.01% 2837
2026
Q1 		$82.4K Buy
5,318
+4,250
+398% +$70.5K ﹤0.01% 2986
2025
Q4 		$20.3K Buy
+1,068
New +$15.3K ﹤0.01% 3517
2023
Q1 		– Sell
-385
Closed -$4K – 3236
2022
Q4 		$4K Buy
385
+328
+575% +$3.96K ﹤0.01% 3385
2022
Q3 		$0 Hold
57
– – ﹤0.01% 4223
2022
Q2 		$0 Buy
+57
New +$646 ﹤0.01% 4304

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Rockefeller Capital Management's NRIX Position: Q2 2026 in Review

Rockefeller Capital Management held its Nurix Therapeutics (NRIX) position steady in Q2 2026 at 5,318 shares worth $129K. The position accounts for ﹤0.01% of the portfolio, ranked #2837.

Rockefeller Capital Management first reported a position in NRIX in Q2 2022 and has held it in 6 quarters since. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Rockefeller Capital Management held 5,318 shares of Nurix Therapeutics worth $129K as of Q2 2026.
  • Rockefeller Capital Management left its Nurix Therapeutics share count unchanged in Q2 2026.
  • Nurix Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #2837 holding.
  • Rockefeller Capital Management first reported a position in Nurix Therapeutics in Q2 2022 and has held it in 6 quarters since.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.